Disease Domain | Count |
---|---|
Infectious Diseases | 1 |
Endocrinology and Metabolic Disease | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 1 |
Bacteriophage therapy | 1 |
Mesenchymal stem cell therapy | 1 |
Top 5 Target | Count |
---|---|
Bacterial DNA gyrase x Bacterial RNA | 1 |
GLP-1R(Glucagon-like peptide 1 receptor) | 1 |
Mechanism Bacterial DNA gyrase modulators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism GLP-1R agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Start Date01 Dec 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
AP-PA02 ( Bacterial DNA gyrase x Bacterial RNA ) | Cystic Fibrosis More | Phase 1/2 |
Human Allogeneic Mesenchymal Stem Cells(Cystic Fibrosis Foundation Therapeutics) | Cystic Fibrosis More | Phase 1 |
TTP-273 ( GLP-1R ) | Cystic fibrosis related diabetes More | Preclinical |
Liprotamase ( AMY2A x Lipase x Protease ) | Exocrine Pancreatic Insufficiency More | Pending |
RCT-201 ( CFTR ) | Cystic Fibrosis More | Pending |